Description
Elanco Animal Health: Powering the Next Leg of Companion-Animal Momentum Through Zenrelia and Portfolio Leverage!
Elanco Animal Health’s fourth-quarter 2025 earnings reveal a company in a robust transition period with both opportunities and challenges. Elanco reported a 9% organic constant currency revenue growth, surpassing expectations in revenue, adjusted EBITDA, and adjusted EPS, a reflection of consistent performance across ten consecutive quarters. This growth is primarily fueled by strong results in U.S. Farm Animal which grew by 17% and U.S. Pet Health by 10%. One of the key drivers of Elanco’s performance was its innovation revenue, which ended the year at $892 million. Looking ahead, the company has increased its 2026 innovation revenue forecast to $1.15 billion, indicating strong confidence in its innovation pipeline. The launch of Credelio Quattro, a groundbreaking parasiticide, exemplifies this innovation. It’s gaining significant traction and rapidly growing market share due to its unique four-ingredient formula.
